

Special Issue

Recent Advances in Radiopharmacy

Message from the Guest Editor

This Special Issue aims to present new trends in the use of innovative radionuclides and their applications in radiopharmacy. The physical or chemical properties of new radionuclides are sometimes unfavorable for the stability of the radiopharmaceuticals obtained with them, which limits their applications. Even if these radionuclides are recognized as being of interest by the scientific community, many questions remain to be answered. Is the growing application of actinium [225Ac] radiolabeled peptides, which are characterized by rapid pharmacokinetic distribution and elimination phases, extensible to other vectors currently used in internal radiotherapy? Is radioactive filiation compatible with non-internalized radiopharmaceuticals? What will be the place of [211At]-Astatine, currently studied at the preclinical level? Are the physical properties of [64Cu]-Copper and its particular metabolism interesting compared with [89Zr]-Zirconium? This Special Issue aims to address these questions, in order to elucidate the future applications of these radionuclides in radiopharmacy.

Guest Editor

Prof. Dr. Alain Faivre-Chauvet

CRCI2NA, INSERM, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France

Deadline for manuscript submissions

closed (31 May 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/121566

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).